The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats. 1980

R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula

The behavioural syndrome caused by L-5-HTP in rats was used for the study of effects of selective 5-HT uptake inhibitors and inhibitors of MAO on central 5-HT receptors. A good correlation was found between the relative potencies of drugs in inhibiting the 5-HT uptake in the rat brain and in intensifying L-5-HTP-induced behavioural stimulation. The potentiation of the L-5-HTP syndrome by the MAO inhibitors correlated with the inhibition of the A- but not of the B-form of the brain monoamine oxidase. In rats treated with the maximally inhibiting dose of a 5-HT uptake inhibitor, MAO inhibitors were still able to increase the intensity of the L-5-HTP syndrome, while the combination of maximal doses of two 5-HT uptake inhibitors did not produce a more intense syndrome than that produced by one 5-HT uptake inhibitor alone. The L-5-HTP-induced behavioural syndrome in rats seems to afford an experimental model allowing the quantification and characterization of the interaction of drugs with serotonin metabolism in the brain.

UI MeSH Term Description Entries
D008297 Male Males
D008732 Methoxydimethyltryptamines Compounds that contain the biogenic monoamine tryptamine and are substituted with one methoxy group and two methyl groups. Members of this group include several potent serotonergic hallucinogens found in several unrelated plants, skins of certain toads, and in mammalian brains. They are possibly involved in the etiology of schizophrenia. Methylbufotenin,5-Methoxy-N,N-Dimethyltryptamine,Methoxydimethyltryptamine,N,N-Dimethyl-5-Methoxytryptamine,5 Methoxy N,N Dimethyltryptamine,N,N Dimethyl 5 Methoxytryptamine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010293 Pargyline A monoamine oxidase inhibitor with antihypertensive properties. Pargyline Hydrochloride,Hydrochloride, Pargyline
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006916 5-Hydroxytryptophan The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant. 5-HTP,Hydroxytryptophan,Oxitriptan,Oxytryptophan,Tryptophan, 5-Hydroxy-,5 Hydroxytryptophan,5-Hydroxy- Tryptophan,Tryptophan, 5 Hydroxy
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine

Related Publications

R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
April 1990, The British journal of psychiatry : the journal of mental science,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
May 2004, Journal of chemical neuroanatomy,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
January 1971, Acta pharmacologica et toxicologica,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
December 1989, The British journal of psychiatry. Supplement,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
May 1997, The American journal of physiology,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
January 1979, Neuropsychobiology,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
March 1968, Life sciences,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
January 1992, Clinical neuropharmacology,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
August 1981, The Journal of pharmacy and pharmacology,
R Ortmann, and P C Waldmeier, and E Radeke, and A Felner, and A Delini-Stula
August 1988, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
Copied contents to your clipboard!